Anupam Rasayan India Ltd. Results

H1FY25 & Q2FY25 Result Announced for Anupam Rasayan India Ltd.

Specialty Chemicals company Anupam Rasayan India announced H1FY25 & Q2FY25 results Q2FY25 Financial Highlights: Total revenue for Q2FY25 was at Rs 2,959 million as compared to Rs 3,956 million in Q2FY24. EBITDA (incl. other income) was at Rs 824 million in Q2FY25 as compared to Rs 1,109 million in Q2FY24, this would translate into 28% EBITDA margin in this quarter. Profit After Tax was at Rs 306 million in Q2FY25 as compared to Rs 487 million in Q2FY24. H1FY25 Financial Highlights: Total revenue for H1FY25 was at Rs 5,562 million as compared to Rs 7,944 million in H1FY24. EBITDA (incl. other income) was at Rs 1,416 million in H1FY25 as compared to Rs 2,247 million in H1FY24, this would translate into 25% EBITDA margin in H1FY25. Profit After Tax was at Rs 428 million in H1FY25 as compared to Rs 1,009 million in H1FY24. Anand Desai, Managing Director, Anupam Rasayan said: "In Q2FY25, we were nearing the end of a demand slump in the Agro segment, and we are now seeing a good recovery. The Pharma and Polymer segments, meanwhile, have been showing robust growth, fuelled by the launch of over 17 new molecules in FY24 and 3 additional molecules in H1FY25. As these products gain traction, we expect their contribution to grow. Additionally, the planned launch of more than 3 new molecules in the coming months should further accelerate growth in these areas. Our consolidated operating revenue for the quarter was Rs 294 crores, representing a QoQ growth of 14%, with a stable EBITDA margin of 28% in Q2FY25. We anticipate revenue to normalize as volumes increase in the latter half of the year. With the new capacity, scaling of recently launched fluorinated molecules, and signed LOIs and contracts, we are optimistic about strong growth over the medium term."

Q4FY24 Quarterly & FY24 Annual Result Announced for Anupam Rasayan India Ltd.

Speciality Chemicals company Anupam Rasayan India announced consolidated Q4FY24 & FY24 results: Q4FY24 Financial Highlights: Total revenue for Q4FY24 was at Rs 4,130 million as compared to Rs 5,042 million in Q4FY23; down 18% YoY. EBITDA (incl. other income) was at Rs 1,047 million in Q4FY24 as compared to Rs 1,416 million in Q4FY23 – degrowth of 26% YoY, this would translate into 25% EBITDA margin in this quarter. Profit After Tax was at Rs 405 million in Q4FY24 as compared to Rs 726 million in Q4FY23 - degrowth of 44% YoY. FY24 Financial Highlights: Total revenue for FY24 was at Rs 15,053 million as compared to Rs 16,105 million in FY23; down 7% YoY. EBITDA (incl. other income) was at Rs 4,109 million as compared to Rs 4,399 million in FY23 – degrowth of 7.0% YoY, this would translate into 27% EBITDA margin. Profit After Tax was at Rs 1,674 million as compared to Rs 2,168 million in FY23 - degrowth of 23% YoY. Speaking on the performance, Anand Desai, Managing Director, Anupam Rasayan commented, “Indian chemical industry including spec chem industry has faced significant headwinds during the last year. However, despite the de-growth in the top-line, we have been able to sustain our profitability and maintain margins at 27% levels on a full year consolidated basis. During the year, the Agro chemical industry in particular faced challenges, however our past sustained efforts in expanding our pharma and polymer portfolio have started yielding results leading to pharma contributing over 9% of revenue in FY24, up from 4% last year. We expect pharma and polymer segment each to further increase their revenue share in double digits by next year. In FY2024, we have focused on expanding our customers, products and end market applications. We have added 17 new molecules, 4 new MNCs including 2 Japanese majors and expanded contribution from polymer and pharma which going forward will lead to balanced product portfolio from end market perspective. We believe that headwinds in the industry may continue for the next two quarters. However, financial year 2025 will be a year of growth for us with our major focus on polymer and pharmaceutical space.”

9MFY24 Result Announced for Anupam Rasayan India Ltd.

Agrochemicals company Anupam Rasayan announced consolidated 9MFY24 results: Total revenue for 9MFY24 was at Rs 10,923 million compared to Rs 11,062 million in 9MFY23, representing a decrease of 1.26% YoY. EBITDA (including other income) was at Rs 3,062 million in 9MFY24 compared to Rs 2,984 million in 9MFY23, reflecting a growth of 2.62% YoY. This translates into a 28.03% EBITDA margin. Profit After Tax was at Rs 1,270 million in 9MFY24 compared to Rs 1,442 million in 9MFY23. Commenting on the performance, Anand Desai, Managing Director of Anupam Rasayan, remarked, “The chemical industry continues to face headwinds impacting our performance for the quarter. This, coupled with clients off-taking minimum required quantities to manage their year-end working capital, has led to a degrowth in our revenues for the quarter. Even during such difficult times, we have been able to maintain our margins steady at 28% for the 9MFY24 on a consolidated basis. I am happy to inform you that, during the quarter, we signed a Letter of Intent worth $61 million i.e., Rs 507 crore for the next 9 years with one of the leading Japanese Chemical companies to supply new age polymer intermediate. I firmly believe that our Japan business will see strong growth in the coming years and will likely become a major business centre for Anupam. As a next step forward in our sustainability journey, the company has decided to invest Rs 59 crore towards setting up a 9.6 MW hybrid (Wind plus Solar) power plant. Post completion of this capex, 65% of the company’s electricity consumption will be from green energy. Overall, I believe FY24 will be a challenging year for the industry but with a resilient and robust business model like ours, I am confident that FY25 will be a year of demand resurgence and strong growth.”

Q1FY24 Quarterly Result Announced for Anupam Rasayan India Ltd.

Agrochemicals company Anupam Rasayan announced Q1FY24 results: Total Revenue at Rs 3,988 million in Q1FY24 as compared to Rs 3,343 million in Q1FY23 – growth of 19% YoY. EBITDA (incl. other revenue) at Rs 1,138 million in Q1FY24 as compared to Rs 892 million in Q1FY23 – growth of 28% YoY. Profit After Tax at Rs 523 million in Q1FY24 as compared to Rs 420 million in Q1FY23 - growth of 25% YoY Speaking on the performance, Anand Desai, Managing Director, Anupam Rasayan commented, “I am delighted at the consistent growth momentum of the Company against a challenging industry backdrop. Our consolidated revenue witnessed a robust 19% YoY growth at Rs 3,988 million. While the falling prices of commodity agrochemicals are putting pressure on margins for the industry, our customised products and robust business model helped us deliver strong EBITDA margins of 29% in Q1FY24. During the quarter, Anupam Rasayan signed an MoU with 3xper Innoventure Ltd., for the supply of targeted and identified new-age pharma molecules using a continuous process. The Company has also signed Letters of Intent (LOIs) worth Rs 40,660 million with Japanese and American MNCs for niche life sciences and specialty chemical molecules. These LOIs reinforce the growing confidence of global MNCs in our technical capabilities and think of us as the trusted partner of choice for high-end customised molecules. These LOIs improves our revenue visibility in the coming years. Our order book remains strong despite a challenging external environment, giving us the confidence to deliver robust growth in FY24 while maintaining margins.”